[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contrast-induced-acute-kidney-injury\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contrast-induced-acute-kidney-injury":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100434398","improving-renal-outcomes-following-coronary-angiography-andor-percutaneous-coronary-interventions-100434398",false,"NCT04936607","ImproviNg rEnal Outcomes Following Coronary angiograPhy and\u002For percuTaneoUs coroNary intErventions","ImproviNg rEnal Outcomes Following Coronary angiograPhy and\u002For percuTaneoUs coroNary intErventions: a Pragmatic, Adaptive, Patient-oriented Randomized Controlled Trial","NEPTUNE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Planned coronary angiogram and\u002For PCI;\n* Willingness to participate and to attend study visits;\n* Expected life expectancy ≥6 months.\n\nExclusion Criteria:\n\n* Cardiogenic or non-cardiogenic shock at the time of the procedure;\n* Emergent procedures (e.g. STEMI);\n* Iodine-based contrast media received within 2 days;\n* Presence of Intra-Aortic Balloon Pump (IABP);\n* Cardiac arrest within 24 hours;\n* Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;\n* Renal replacement therapy;\n* Severe aortic or mitral disease;\n* LVEF \\\u003C30%.","ALL","18 Years",{"count":20,"type":21},1158,"ESTIMATED","INTERVENTIONAL",[24],"NA","The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and\u002For percutaneous coronary intervention (PCI).",[27],"Contrast-Induced Acute Kidney Injury",[29,30,31,32,33,34,35,36],"Randomized controlled trial","Pragmatic trial","Adaptive trial","Patient-oriented trial","Contrast-induced Nephropathy","Acute Kidney Injury","Coronary angiography","Percutaneous coronary intervention","RECRUITING","2025-12-01",{"date":40,"type":41},"2025-12-08","ACTUAL",{"date":43,"type":41},"2021-06-28",{"date":45,"type":21},"2027-07-31",{"name":47,"class":48},"Montreal Heart Institute","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":49},"100610773","use-of-flozins-empagliflozindapagliflozin-for-prevention-of-aki-100610773","NCT07231939","Use of Flozins (Empagliflozin\u002FDapagliflozin) for Prevention of AKI","FLOzins for pREveNtion of Contrast-inducEd Acute Kidney Injury (FLORENCE) Study","FLORENCE","Inclusion Criteria:\n\n* all consecutive patients who underwent PCI or coronary angiography during the study period for whom the variables required for the analysis are available\n\nExclusion Criteria:\n\n* unavailability of variables required for the analysis, volume\n* contrast agent volume \\\u003C50 mL or \\>500 mL.",{"count":59,"type":21},4000,"OBSERVATIONAL","All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion.\n\nThe final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available.\n\nThe primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.",[63,34,27,64],"Coronary Artery Disease","Percutaneous Coronary Intervention",[66,67,68,69,70],"AKI","contrast-induced acute kidney injury","PCI","coronary angiography","acute kidney injury","2025-11-14",{"date":73,"type":41},"2025-11-17",{"date":75,"type":41},"2025-11-01",{"date":77,"type":21},"2026-03-31",{"name":79,"class":48},"Collegium Medicum w Bydgoszczy"]